Topiramate Interactions[ edit ] Topiramate has many drug-drug interactions.
Some of the most common are listed below: As topiramate inhibits carbonic anhydraseuse with other inhibitors of carbonic anhydrase e. Topiramate itself is a weak inhibitor of CYP2C19 and induces CYP3A4 ; a decrease in plasma levels of estrogens and digoxin has been noted during topiramate therapy.
This can reduce the effectiveness of oral contraceptives birth control pills ; use of alternative birth control methods is recommended. As topiramate may result in acidosis other treatments that also do so may worsen this effect.
Az epilepszia területén az Élelmiszer- és Gyógyszerügyi Hatóság FDA öt új antiepileptikus gyógyszert hagyott jóvá az öt év alatt és fycompa fogyás. Gyógyszerkereső Mit gyógyítanak ezek a gyógyszerek?
Topiramate is quickly absorbed fycompa fogyás oral use. The remainder is extensively metabolized by hydroxylationhydrolysisand glucuronidation. Several cellular targets have been proposed to be relevant to the therapeutic activity of topiramate.
There is evidence that topiramate may alter the activity of its targets by modifying their phosphorylation state instead of by a direct action.
Although topiramate does inhibit high-voltage-activated calcium channels, the relevance to clinical activity is uncertain.
JUDIT 20 KILÓ FOGYÁSÁNAK TÖRTÉNETE
Fycompa fogyás on specific GABA-A receptor isoforms could also contribute to the antiseizure activity of the drug. Topiramate selectively inhibits cytosolic type II and membrane associated type IV forms of carbonic anhydrase. The action on carbonic anhydrase isoenzymes may contribute to the drug's side-effects, including its propensity to cause metabolic acidosis and calcium phosphate kidney stones.
Topiramate inhibits maximal electroshock and pentylenetetrazol -induced seizures as well as partial and secondarily generalized tonic-clonic seizures in the kindling model, findings predictive fogyás trokendi xr a broad spectrum of activities clinically. Its action on fogyás trokendi xr permeability transition pores has been proposed as a mechanism.
Maryanoff and Joseph F. Gardocki during their research work at McNeil Pharmaceuticals.